In yesterday’s Wall Street session, FibroGen Inc. (NASDAQ:FGEN) shares traded at $2.22, down -6.72% from the previous session.
7 analysts cover FibroGen Inc. (NASDAQ:FGEN), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $37.20 and a low of $3.00, we find $20.00. Given the previous closing price of $2.38, this indicates a potential upside of 740.34 percent. FGEN stock price is now -82.02% away from the 50-day moving average and -86.74% away from the 200-day moving average. The market capitalization of the company currently stands at $224.15M.
The stock has received a hold rating from 5 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $20.04 as their price target over the next twelve months.
In other news, Henderson Jeffrey William, Director sold 2,000 shares of the company’s stock on Jul 11. The stock was sold for $5,380 at an average price of $2.69. Upon completion of the transaction, the Director now directly owns 32,866 shares in the company, valued at $72962.52. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 07, Chief Executive Officer Conterno Enrique A sold 1,880 shares of the business’s stock. A total of $5,264 was realized by selling the stock at an average price of $2.80. This leaves the insider owning 374,722 shares of the company worth $0.83 million. Insiders disposed of 270,140 shares of company stock worth roughly $0.6 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FGEN stock. A new stake in FibroGen Inc. shares was purchased by ARTISAN PARTNERS LIMITED PARTNERSHIP during the first quarter worth $3,000,000. ASSENAGON ASSET MANAGEMENT S.A. invested $2,985,000 in shares of FGEN during the first quarter. In the first quarter, EVENTIDE ASSET MANAGEMENT, LLC acquired a new stake in FibroGen Inc. valued at approximately $2,131,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in FGEN for approximately $719,000. PRUDENTIAL FINANCIAL INC purchased a new stake in FGEN valued at around $516,000 in the second quarter. In total, there are 225 active investors with 78.70% ownership of the company’s stock.
On Thursday morning FibroGen Inc. (NASDAQ: FGEN) stock kicked off with the opening price of $2.3900. During the past 12 months, FibroGen Inc. has had a low of $2.36 and a high of $25.69. The fifty day moving average price for FGEN is $12.0342 and a two-hundred day moving average price translates $16.6873 for the stock.
The latest earnings results from FibroGen Inc. (NASDAQ: FGEN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.81, missing analysts’ expectations of -$0.75 by -0.06. This compares to -$0.68 EPS in the same period last year. The company reported revenue of $36.16 million for the quarter, compared to $60.83 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -40.55 percent. For the current quarter, analysts expect FGEN to generate $34.74M in revenue.
FibroGen Inc.(FGEN) Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
